RBC8 NEW
| Price | $93 | $158 | $313 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: RBC8 | CAS No.: 361185-42-4 |
| Purity: 99.86% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | RBC8 |
| Description | RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras. |
| Cell Research | Growth inhibition of human lung cancer cells by the compounds is measured under anchorage-independent conditions in soft agar. Cells are seeded into 6-well plates (coated with a base layer made of 2.0 ml of 1% low-melting-point agarose) at 15,000 cells per well in 3.0 mL of 0.4% low-melting-point agarose containing various concentration of drug. Two to four weeks (depending on the cell line) after incubation, the cells are stained with 1.0 mg ml?1 nitroblue tetrazolium, and colonies are counted under a microscope. The IC50 values are defined as the concentration of drug that resulted in a 50% reduction in colony number compared with the DMSO-treated control. (Only for Reference) |
| In vitro | In mice bearing H358 xenografts, RBC8 administered intraperitoneally (i.p.) at a dosage of 50 mg/kg specifically inhibits RalA and RalB, thereby suppressing tumor growth. |
| In vivo | Within living cells, RBC8k can induce a chemical shift change in RalB-GDP, thereby diminishing the activation of RalA. In Ral-dependent H2122 (IC50: 3.5 μM) and H358 (IC50: 3.4 μM) models, RBC8 leads to the inhibition of anchorage-independent growth. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.71 mM), Sonication is recommended. DMSO : 42.4 mg/mL (99.89 mM), Sonication is recommended. |
| Keywords | RBC-8 | RBC8 | RBC 8 | Ras | Inhibitor | inhibit | GTPases RalB | GTPases RalA |
| Inhibitors Related | Undecane | Esculin | Bisphenol A | RMC-9805 | Fumaric acid | Astragaloside IV | MRTX1133 | D-Psicose | Sotorasib | Chloramphenicol | Daraxonrasib | Metacetamol |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Autophagy Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | GPCR Compound Library | Anti-Cancer Compound Library | MAPK Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00 |
VIP6Y
|
Career Henan Chemica Co
|
2024-10-22 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY